Dual inhibition of SGLT 1 and 2 by sotagliflozin alleviates intracellular sodium overload and improves cardiometabolic remodelling in uraemic cardiomyopathy
Cardiovascular Research · 2026
DOI: 10.1093/cvr/cvag167 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cardiovascular Research, 2026. Verfasst von Megan Young und 22 weiteren Autor:innen. Beteiligte Einrichtung: William Harvey Research Institute, John Vane Science Centre, Barts and the London Faculty of Medicine and Dentistry, Queen Mary University of London,…. Hauptthemen laut MEDLINE: Sodium-Glucose Transporter 1, Sodium-Glucose Transporter 2 Inhibitors, Cardiomyopathies, Sodium-Glucose Transporter 2. Die Arbeit nennt 90 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Wellcome Trust, British Heart Foundation, St Thomas' NHS Foundation Trust.
Abstract (Originalsprache)
Aims
Chronic kidney disease (CKD) is associated with uraemic cardiomyopathy characterized by early metabolic dysfunction. Elevated myocardial intracellular sodium (Naᵢ) has emerged as a driver of cardiometabolic remodelling, however, its role in CKD and therapeutic modulation remains unclear. We investigated whether dual sodium-glucose cotransporter (SGLT)1/2 inhibition with sotagliflozin (SOTA) targets Naᵢ and improves cardiac metabolism in CKD. Methods and results CKD was induced in male Wistar rats by 5/6 nephrectomy and assessed after 4 weeks. Cardiac phenotype was evaluated using in vivo echocardiography and ex vivo Langendorff perfusion combined with 23Na and 31P NMR spectroscopy. CKD hearts exhibited preserved systolic but impaired diastolic function and a marked elevation in myocardial Naᵢ, identifying Naᵢ overload as an early feature of uraemic cardiomyopathy. Cardiac metabolomic profiling and flux modelling demonstrated widespread suppression of central carbon metabolism, redox imbalance despite preserved PCr/ATP. In silico electrophysiological simulations predicted Naᵢ-driven Ca2+ dysregulation consistent with in vivo diastolic dysfunction. Chronic SOTA treatment (3 weeks, in vivo) normalized myocardial Naᵢ and partially reversed metabolic remodelling. Acute SOTA exposure (20 min, Langendorff-perfusion) similarly reduced Naᵢ in CKD hearts but not in controls, indicating a direct, disease-selective myocardial effect. Naᵢ normalization was accompanied by improved redox state and restoration of mitochondrial metabolic flux, without changes in expression of canonical Na + -handling proteins.
Conclusion
Myocardial Naᵢ overload emerges as an early and potentially modifiable feature of uraemic cardiomyopathy. Dual SGLT1/2 inhibition with SOTA directly lowers Naᵢ and improves cardiac metabolic homeostasis, supporting Naᵢ as a mechanistically relevant and potentially targetable pathway in CKD-related cardiac remodelling.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- William Harvey Research Institute, John Vane Science Centre, Barts and the London Faculty of Medicine and Dentistry, Queen Mary University of London, Charterhouse Square, London EC1M 6BQ, UK.
- Department of Cardiology, Smidt Heart Institute, Cedars Sinai Medical Center, Los Angeles, USA.
- The MR Research Centre and The PET Centre, Clinical Medicine, Aarhus University, Aarhus 8200, Denmark.
- Clarendon Laboratory, Department of Physics, University of Oxford, Oxford, UK.
- Department of Computer Science, University of Oxford, Oxford, UK.
- Cancer Research UK Scotland Centre, Institute of Genetics and Cancer, University of Edinburgh, Edinburgh, UK.
ORCID-Profile: Megan Young, Andrew Tinker, Michelangelo Campanella, Nay Aung, Dunja Aksentijevic
Förderung
- Wellcome Trust
- British Heart Foundation
- St Thomas' NHS Foundation Trust
- BHF Centre of Research Excellence
- Fondation ARC pour la Recherche sur le Cancer
- COST Action EU-METAHEART
- Queen Mary University of London
- Barts Metabolism Network
Zitieren
APA
Young, M., Karlstaedt, A., Dambure, S., Miller, J. J. J. J., Guo, T., Zhou, X., Ramchunder, Z., Gonzalez Marques Junior, J., Nobles, M., Tinker, A., Kim, K., Purcell, A. R., Glastras, S. J., Cullen, F., Eykyn, T. R., Von Kriegsheim, A., Rodriguez, B., Campanella, M., Shattock, M. J., …, & Aksentijevic, D. (2026). Dual inhibition of SGLT 1 and 2 by sotagliflozin alleviates intracellular sodium overload and improves cardiometabolic remodelling in uraemic cardiomyopathy. Cardiovascular Research. https://doi.org/10.1093/cvr/cvag167
Vancouver
Young M, Karlstaedt A, Dambure S, Miller JJJJ, Guo T, Zhou X, et al. Dual inhibition of SGLT 1 and 2 by sotagliflozin alleviates intracellular sodium overload and improves cardiometabolic remodelling in uraemic cardiomyopathy. Cardiovascular Research. 2026. doi:10.1093/cvr/cvag167
BibTeX
@article{Young2026,
author = {Young, Megan and Karlstaedt, Anja and Dambure, Sanushi and Miller, Jack J J J and Guo, Tong and Zhou, Xin and Ramchunder, Zenouska and Gonzalez Marques Junior, Jair and Nobles, Muriel and Tinker, Andrew and Kim, Kyuongmin and Purcell, Amanda R and Glastras, Sarah J and Cullen, Fenn and Eykyn, Thomas R and Von Kriegsheim, Alex and Rodriguez, Blanca and Campanella, Michelangelo and Shattock, Michael J and Aung, Nay and Cabrera, Claudia P and Yaqoob, Magdi M and Aksentijevic, Dunja},
title = {Dual inhibition of SGLT 1 and 2 by sotagliflozin alleviates intracellular sodium overload and improves cardiometabolic remodelling in uraemic cardiomyopathy},
journal = {Cardiovascular Research},
year = {2026},
doi = {10.1093/cvr/cvag167}
}
EUVIMED